The Role of Striatal Glutamatergic System in Haloperidol-Induced Dopamine Receptor Supersensitivity and Effects of Monosialoganglioside GM1
暂无分享,去创建一个
[1] B. Sabel,et al. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding. , 1994, The Journal of pharmacology and experimental therapeutics.
[2] J. Desce,et al. Presynaptic control of dopamine synthesis and release by excitatory amino acids in rat striatal synaptosomes , 1994, Neurochemistry International.
[3] Micaela Morelli,et al. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions , 1994, Trends in Neurosciences.
[4] C. Y. Kao,et al. Enhancement of beta-adrenergic receptor activation of maxi-K+ channels by GM1 ganglioside. , 1994, Biochemical and biophysical research communications.
[5] B. Sabel,et al. A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers , 1994, Neuroscience Letters.
[6] N. Guzman,et al. In vivo monitoring of glutamate in the brain by microdialysis and capillary electrophoresis with laser-induced fluorescence detection. , 1993, Journal of chromatography. A.
[7] B. Lössner,et al. Glutamate Binding to Brain Membranes Is Increased in Pentylenetetrazole‐Kindled Rats , 1993, Journal of neurochemistry.
[8] H. Manev,et al. Ganglioside derivative LIGA20 reduces NMDA neurotoxicity in neonatal rat brain. , 1992, Neuroreport.
[9] M. Shifman. The effect of gangliosides upon recovery of aspartate/glutamatergic synapses in striatum after lesions of the rat sensorimotor cortex , 1991, Brain Research.
[10] R. Waziri,et al. Evidence of glutamatergic deficiency in schizophrenia , 1991, Neuroscience Letters.
[11] K. Reymann,et al. N-methyl-D-aspartate stimulates the release of dopamine from rat hippocampal slices. , 1990, Biomedica biochimica acta.
[12] T. Sumi,et al. Evoked release of endogenous amino acids from rat striatal slices and its modulation. , 1989, European journal of pharmacology.
[13] G Maura,et al. Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. , 1988, The Journal of pharmacology and experimental therapeutics.
[14] B. Sabel,et al. Pharmacological Approaches to the Treatment of Brain and Spinal Cord Injury , 1988, Springer US.
[15] B. Sabel. Anatomic Mechanisms Whereby Ganglioside Treatment Induces Brain Repair , 1988 .
[16] I. Divac,et al. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain , 1981, Neuroscience.
[17] J. Leysen,et al. Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. , 1978, Biochemical pharmacology.
[18] A. Young,et al. Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[19] L. Svennerholm. CHROMATOGRAPHlC SEPARATION OF HUMAN BRAIN GANGLIOSIDES * , 1963, Journal of neurochemistry.
[20] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.